26095-36-3 Usage
Uses
Used in Pharmaceutical Industry:
5-Morpholin-4-ylmethyl-furan-2-carboxylic acid is used as an active pharmaceutical ingredient for its antifungal and antibacterial activity, serving as a potential candidate for the development of new drugs to treat infectious diseases.
Used in Drug Synthesis:
5-Morpholin-4-ylmethyl-furan-2-carboxylic acid is used as a key intermediate in the synthesis of other biologically active compounds, leveraging its furan ring structure to create novel therapeutic agents with diverse applications in medicine.
Check Digit Verification of cas no
The CAS Registry Mumber 26095-36-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,6,0,9 and 5 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 26095-36:
(7*2)+(6*6)+(5*0)+(4*9)+(3*5)+(2*3)+(1*6)=113
113 % 10 = 3
So 26095-36-3 is a valid CAS Registry Number.
InChI:InChI=1/C10H13NO4/c12-10(13)9-2-1-8(15-9)7-11-3-5-14-6-4-11/h1-2H,3-7H2,(H,12,13)
26095-36-3Relevant academic research and scientific papers
Benzothiazole compounds and medical application
-
Paragraph 0220; 0024; 0230, (2020/10/21)
The invention discloses a benzothiazole compound and medical application thereof, particularly relates to a benzothiazole compound shown as a formula I and medical application thereof, and especiallyrelates to application of the benzothiazole compound serving as a USP7C-terminal structural domain regulating agent in medicines for preventing and treating myelodysplastic syndromes and malignant tumors. The benzothiazole compound shown in the formula I or the pharmaceutically acceptable salt or solvate of the benzothiazole compound has strong binding force with USP7C-terminal protein; and the protein level of DNMT1 in tumor cells can be reduced, so that the compound can be applied to the preparation of USP7 regulators, has a remarkable anti-tumor cell proliferation effect, and can be used for preparing medicines for preventing or treating myelodysplastic syndrome and malignant tumors.
